Please assess the completion status of the following clinical trial:

Trial Title: Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be platinum resistant~* Patients will be included in the study based on the following criteria:~  * No prior anthracycline use~ * PS less or equal 2~ * Lab values within certain limits (ANC greater 1000, platelets greater 100,000; ALT, AST 2 time ULN, creatinine less 2.0)~ * No more than 3 prior chemotherapy regimens, only 2 of which can have included platinum-containing regimens~ * Use of effective means of contraception in subjects of child-bearing potential~Exclusion Criteria:~1. Disease-Specific Exclusions:~   * Evidence of complete or partial bowel obstruction~  * Need for IV hydration or TPN~  * Greater 2 prior abdominal surgeries~  * History of gastrointestinal perforation~  * Gastrointestinal perforation due to any other cause within the last 6 months~2. General Medical Exclusions:~   * Inability to comply with study and/or follow-up procedures~  * Life expectancy of less than 12 weeks~  * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study~3. Avastin-Specific Exclusions~   * Inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure greater 100 mmHg on antihypertensive medications)~  * Any prior history of hypertensive crisis or hypertensive encephalopathy~  * New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)~  * History of myocardial infarction or unstable angina within 6 months prior to study enrollment~  * History of stroke or transient ischemic attack within 6 months prior to study enrollment~  * Known CNS disease~  * Significant vascular disease (e.g., aortic aneurysm, aortic dissection)~  * Symptomatic peripheral vascular disease~  * Evidence of bleeding diathesis or coagulopathy~  * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study~  * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment~  * History of abdominal fistula, or intra-abdominal abscess within 6 months prior to study enrollment~  * Serious, non-healing wound, ulcer, or bone fracture~  * Proteinuria at screening as demonstrated by either:~     * Urine protein:creatinine (UPC) ratio 1.0 at screening OR~    * Urine dipstick for proteinuria greater or equal 2plus (patients discovered to have greater or equal 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate less or equal 1g of protein in 24 hours to be eligible)~  * Known hypersensitivity to any component of Avastin~  * Pregnant (positive pregnancy test) or lactating. No effective means of contraception (men and women) in subjects of child-bearing potential

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm: Doxil and Avastin (Type: EXPERIMENTAL): Patients receive both agents, doxil and Avastin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete